This announcement is a separate document:
アステラス製薬：中国の国家医薬品管理局は、転移性ホルモン感受性前立腺がんに対するXTANDI（エンザルタミド）を承認しました
Astellas Pharma: China's National Medical Products Administration has approved XTANDI (enzalutamide) for metastatic hormone-sensitive prostate cancer.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.